This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
With no strong resistance manifesting to oppose the psychedelic renaissance, it appears these drugs have re-emerged from underground for a permanent place in our culture.
The revered wellness brand wields proven business savvy to innovate, disrupt and equalize through its ketamine clinics.
Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing in psychedelic stocks.
Filmmaker Matthew Dunehoo, the director of our “Spotlight in Focus” series, reflects on a 1980 sci-fi horror movie that every psychonaut should see, and can probably relate to.
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.
The Oregon Health Authority has until December 31, 2022, to finalize the framework, paving the way for licensure in early 2023.
“The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” says Dr. Deepak Chopra.
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.
Cathie Wood and Ark Invest buying psychedelic stocks will be significant for the industry, as Wood holds a megaphone with which she communicates to retail growth investors.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.